drugset
drugset / Trial / NCT05154669

Integrating Financial Coaching and Smoking Cessation Coaching

NCT05154669 ↗

Phase 3 Recruiting 602 enrolled NYU Langone Health National Cancer Institute (NCI) · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

This study conduct a two-arm, parallel-group randomized controlled trial. The study will recruit and randomize 900 smokers (n=450 per arm) to either: (1) Control: Standard Smoking Cessation Counseling or (2) Intervention: Integrated Financial-Smoking Cessation Counseling.

Timeline

Start
2022-12-08
Primary completion
2029-12-01
Completion
2029-12-01

Drugs

EvaluationDrugModalityDoseRoute
Background Nicotine Unknown 2 mg Other
Background Nicotine Unknown 4 mg Other
Background Nicotine Unknown 7 mg Other
Background Nicotine Unknown 14 mg Other
Background Nicotine Unknown 21 mg Other

Indications

No indication recorded.